Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial

Autor(es)

Preti, Rony Carlos ^[1] ; Vasquez Ramirez, Lisa Mariel ^[1] ; Ribeiro Monteiro, Mario Luiz ^{[1, 2]} ; Carra, Mario Kehdi ; Pelayes, David E. ^{[3, 4]} ; Takahashi, Walter Yukihiko ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Med, Dept Ophthalmol, BR-04130010 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Sch Med, Dept Endocrinol, BR-04130010 Sao Paulo - Brazil

^[3] Univ Buenos Aires, Area Ophthalmol, Buenos Aires, DF - Argentina

^[4] Maimonides Univ, Ctr Appl Res & High Complex Ophthalmol, Buenos Aires, DF - Argentina

• Tipo de documento: Artigo Científico
• Fonte: BRITISH JOURNAL OF OPHTHALMOLOGY; v. 97, n. 7, p. 885-889, JUL 2013.
• Citações Web of Science: 11

Resumo

Purpose To compare the effect on contrast sensitivity (CS) measurements of panretinal photocoagulation (PRP) associated with intravitreal bevacizumab (IVB) injections versus PRP alone in high risk proliferative diabetic retinopathy (HR-PDR). Design Prospective, randomised, masked, controlled trial. Participants 42 patients with HR-PDR with visual acuity >= 20/200. Methods Eyes were randomised to one of two groups: one underwent PRP and IVB injections (study group) and the other PRP alone (control group). PRP was performed three times during the study and IVB injection was administered twice. Main outcome measures Mean change in CS threshold scores between and within groups, from baseline to 6 months. Results Seven patients presented with vitreous haemorrhage and were removed from the study. Mean results for CS threshold (at 1.5, 3, 6, 12 and 18 cycles per degree (cpd) frequencies) for patients with and without diabetic macular oedema showed no significant differences (p>0.05 for all comparisons) between the two groups. In 35 eyes in the control group, compared with baseline values, there was significant worsening (p<0.05) of CS at 1.5, 12 and 18 cpd after 1 month, at 12 cpd after 3 months, and at 6 and 12 cpd after 6 months. In the study group, there was significant improvement in CS at 3 cpd, 3 months after treatment. Conclusions In eyes with HR-PDR, PRP treatment is associated with deterioration of CS while adjuvant use of bevacizumab prevents such deterioration. CS evaluation seems to support the adjuvant use of bevacizumab when using PRP for the treatment of HR-PDR. (AU)

• Processo FAPESP: 09/08895-1 - Avaliação estrutural e funcional da mácula nos pacientes com retinopatia diabética proliferativa submetidos à panfotocoagulação associada a bevacizumab
• Beneficiário: Walter Yukihiko Takahashi
• Linha de fomento: Auxílio à Pesquisa - Regular